split-banner-image

ATLAS

Closed

ANZ 9602: ATLAS

BCT Study Chair:

Shane White

Adjuvant tamoxifen longer against shorter (ATLAS) clinical trial in early breast cancer.

international

14468

INTERNATIONAL

Total number of trial

participants internationally

australia & new zealand

784

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

institutions

35

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

ATLAS PUBLICATIONS

2013

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VHM, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou M-F, Inbar M, Khaled H, Keilanowska J, Kwan W-H, Mathew BS, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Peinkowski T, Ragan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R, for the ATLAS Collaborative Group The Lancet 2013; 381805-816, Journal

2011

Optimal adjuvant therapy for very young breast cancer patients.

Francis PA. The Breast 2011; 20(4):297-302, Journal

2002

Choosing between endocrine therapy and chemotherapy – or is there a role for combination therapy?

Forbes JF, Gradishar WJ, Ravdin PM. Breast Cancer Res Treat 2002; 75S37-S44, Journal

Institutions